These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 6323221)

  • 61. [Differential therapeutic topics in antihypertensive therapy. What can angiotensin-converting enzyme inhibitors accomplish?].
    Noack E
    Z Kardiol; 1988 Jul; 77(7):413-24. PubMed ID: 2850683
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Treatment of hypertension with angiotensin converting enzyme inhibitors.
    Johnston CI
    Aust N Z J Med; 1984 Aug; 14(4):509-13. PubMed ID: 6097208
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Role of angiotensin converting enzyme inhibitors in essential and renal hypertension. Effects of captopril and enalapril on renin-angiotensin-aldosterone, renal function and hemodynamics, salt and water excretion, and body fluid composition.
    Bauer JH
    Am J Med; 1984 Aug; 77(2A):43-51. PubMed ID: 6206722
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Angiotensin converting enzyme inhibition. Unique and effective therapy for hypertension and congestive heart failure.
    DiBianco R
    Postgrad Med; 1985 Oct; 78(5):229-41, 244, 247-8. PubMed ID: 2864682
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Clinical pharmacology of ACE inhibitors].
    Hitzenberger G
    Wien Med Wochenschr; 1990 Jan; 140(1-2):12-8. PubMed ID: 2408245
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Acute haemodynamic, hormonal and electrolyte effects and short-term clinical response to enalapril in heart failure.
    Fitzpatrick D; Nicholls MG; Ikram H; Espiner EA
    J Hypertens Suppl; 1983 Oct; 1(1):147-53. PubMed ID: 6100604
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Do vasodilators help in chronic heart failure?].
    Slany J
    Wien Klin Wochenschr; 1987 Mar; 99(5):139-44. PubMed ID: 2883777
    [TBL] [Abstract][Full Text] [Related]  

  • 68. An overview of the clinical pharmacology of enalapril.
    Davies RO; Gomez HJ; Irvin JD; Walker JF
    Br J Clin Pharmacol; 1984; 18 Suppl 2(Suppl 2):215S-229S. PubMed ID: 6099737
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Undesirable effects and interaction to angiotensin converting enzyme inhibitors therapy].
    Ionescu SD; Sandru V; Leuciuc E; Manea P; Burdujan A; Tovarniţchi S; Cosovanu A
    Rev Med Chir Soc Med Nat Iasi; 2002; 106(1):128-31. PubMed ID: 12635373
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Hemodynamic and antihypertensive effects of the new oral angiotensin-converting-enzyme inhibitor MK-421 (enalapril).
    Fouad FM; Tarazi RC; Bravo EL; Textor SC
    Hypertension; 1984; 6(2 Pt 1):167-74. PubMed ID: 6327515
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Converting-enzyme inhibition for severe chronic heart failure: views from a skeptic.
    Packer M
    Int J Cardiol; 1985 Feb; 7(2):111-20. PubMed ID: 2982750
    [No Abstract]   [Full Text] [Related]  

  • 72. Adverse effects of converting-enzyme inhibition in patients with severe congestive heart failure: pathophysiology and management.
    Packer M; Kessler PD; Gottlieb SS
    Postgrad Med J; 1986; 62 Suppl 1():179-82. PubMed ID: 3022272
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Hemodynamic effects of new angiotensin converting enzyme inhibitors during continuous angiotensin I infusion on conscious dogs.
    Hütter JF; Dehn A; Schmidt W
    Arzneimittelforschung; 1988 Jul; 38(7):896-901. PubMed ID: 2849951
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The clinical pharmacology of antihypertensive drugs.
    Lowenthal DT; Saris SD; Haratz A; Packer J; Porter RS; Conry K
    J Hypertens Suppl; 1984 Dec; 2(2):S13-24. PubMed ID: 6152830
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Angiotensin-converting enzyme inhibitors: recent therapeutic aspect].
    Shionoiri H; Shigemasa T; Takasaki I
    Nihon Rinsho; 1997 Aug; 55(8):2067-74. PubMed ID: 9284425
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [What have we learned about inhibitors of the renin-angiotensin system?].
    Waeber B; Nussberger J; Brunner HR
    Ann Endocrinol (Paris); 1986; 47(3):167-77. PubMed ID: 3022638
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Clinical pharmacology and therapeutic applications of the new oral converting enzyme inhibitor, enalapril.
    Riley LJ; Vlasses PH; Ferguson RK
    Am Heart J; 1985 May; 109(5 Pt 1):1085-9. PubMed ID: 2986440
    [No Abstract]   [Full Text] [Related]  

  • 78. [Effects of 3 different angiotensin converting enzyme inhibitors, MK 421, SQ 14225 and SA 446 on renal function and blood pressure in patients with essential hypertension].
    Tajima J; Abe K; Yasujima M; Tanno M; Yoshinaga K
    Nihon Jinzo Gakkai Shi; 1984 Jun; 26(6):779-89. PubMed ID: 6096607
    [No Abstract]   [Full Text] [Related]  

  • 79. Angiotensin-converting enzyme inhibitors: are they all alike?
    Case DB
    J Clin Hypertens; 1987 Sep; 3(3):243-56. PubMed ID: 2822859
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Clinical pharmacology of enalapril.
    Abrams WB; Davies RO; Gomez HJ
    J Hypertens Suppl; 1984 Dec; 2(2):S31-6. PubMed ID: 6100874
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.